Follow us on social

Shutterstock_1854498166-scaled

Biden takes a vital step on vaccine patents — but more action is needed

U.S. support for a patent waiver must be coupled with technology transfers, information sharing, and a coordinated global effort to distribute vaccines.

North America

The Biden administration’s announcement that it will support a WTO patent waiver for COVID-19 vaccines is a welcome step towards ending the global pandemic — but it must be followed by coordinated efforts to boost vaccine production through technology transfer, information sharing, and increased financing to have its promised effect.

The move is a heel-turn for the administration, which in March helped block a proposal led by India and South Africa to waive patents for Covid vaccines, treatments, and vital medical supplies in order to enable the production of affordable generics, particularly in the developing world.

This reversal, announced by U.S. Trade Representative Katherine Tai, comes after months of pressure from activists and public health experts around the globe.

U.S. support does not itself guarantee passage of a patent waiver, as the United States was previously joined in blocking the measure by the United Kingdom, the European Union, and a handful of other countries. It does, however, make it vastly more likely that remaining holdouts will shift their positions. (At this time, New Zealand has already suggested it will move to support the waiver).

While the administration’s announcement is undoubtedly good news, crucial questions remain. Notably, Tai’s statement does not say that the U.S. will support the specific proposal put forward by India and South Africa. This suggests that the United States may advocate for a modified or narrower plan in WTO negotiations. Tai’s announcement states only that the U.S. will support a waiver for vaccines, not for treatments and medical supplies as included in the earlier proposal. To maximize the benefits of a waiver, the Biden administration must be pushed to support the broadest possible proposal, ideally including COVID treatments and medical supplies.

Most importantly, the waiver will require follow-on action in the form of technology transfer and information sharing. While patents are a primary barrier to broader vaccine production, new manufacturers will also need access to key technologies and production information. 

The Biden administration should begin working now to facilitate technology transfer through the World Health Organization’s COVID-19 Technology Access Pool and to share manufacturing information held by Pfizer, Moderna, and others. It should also come up with a plan to finance scaled-up production and distribution of vaccines worldwide.

The administration cannot hesitate in taking these next steps. Its embrace of a patent waiver offers an unprecedented opportunity to bring a more swift end to the pandemic — and with cases surging in devastating outbreaks around the world, there is no time to spare.


(shutterstock.com)
North America
Trump and Putin on phone
Top photo credit: Donald Trump (White House photo) and Vladimir Putin (Office of the Russian Federation President)
US-Russia talks: The rubber finally hits the road

Good, bad and ugly: Impact of US Iran strikes on Russia war talks

Europe

To a considerable degree, President Donald Trump won the presidency in 2024 because voters embraced his message of keeping America out of protracted conflicts and his promise to end the war in Ukraine.

The administration has made substantial operational headway, particularly in reopening stable channels for dialogue with Russia, but it has proven difficult to arrive at a framework for a negotiated settlement that enjoys buy-in from all the stakeholders — Ukraine, Russia, and Europe.

keep readingShow less
Trump Netanyahu in Washington
Top photo credit: Donald Trump and Benjamin Netanyahu (Joshua Sukoff / Shutterstock.com)

Netanyahu returns to DC — in triumph or with more to ask?

Middle East

On Monday, Israeli Prime Minister Netanyahu will arrive in Washington for his third visit of Trump’s second term. Today also marks 21 months of Israel’s war on Gaza. The purpose of the visit remains unclear, and speculation abounds: will Trump and Netanyahu announce a real ceasefire in Gaza? Will Syria join the Abraham Accords? Or might Trump greenlight even broader Israeli action against Iran?

Before Netanyahu’s visit, Trump posted an ultimatum on Truth Social, claiming Israel had agreed to a 60-day ceasefire. He urged Hamas to accept the terms, threatening that “it will only get worse” if it doesn’t. Although Trump intended to pressure Hamas, reiterating a longstanding narrative that portrays the group as the obstacle to peace, Hamas has long maintained that it will only accept a ceasefire if it is part of a process that leads to a permanent end to Israel’s war and its complete withdrawal from the enclave. Netanyahu, for his part, remains adamant that the war must continue until Hamas is eliminated, a goal that even the IDF has described as not militarily viable.

keep readingShow less
POGO The Bunker
Top image credit: Project on Government Oversight

Yes to 'Department of War' name change

Military Industrial Complex

The Bunker appears originally at the Project on Government Oversight and is republished here with permission.

keep readingShow less

LATEST

QIOSK

Newsletter

Subscribe now to our weekly round-up and don't miss a beat with your favorite RS contributors and reporters, as well as staff analysis, opinion, and news promoting a positive, non-partisan vision of U.S. foreign policy.